MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Search

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

74.82 -0.4

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

74.38

Max

74.84

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-100M

-229M

Pardavimai

46M

203M

Pelno marža

-112.808

Darbuotojai

1,402

EBITDA

4.7B

4.6B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+29.95% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.7B

12B

Ankstesnė atidarymo kaina

75.22

Ankstesnė uždarymo kaina

74.82

Naujienos nuotaikos

By Acuity

50%

50%

154 / 349 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-03 04:27; UTC

Svarbiausios naujienos

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

2026-04-03 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-04-03 18:30; UTC

Svarbiausios naujienos

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

2026-04-03 18:14; UTC

Rinkos pokalbiai

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

2026-04-03 17:50; UTC

Rinkos pokalbiai

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

2026-04-03 17:44; UTC

Įsigijimai, susijungimai, perėmimai

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

2026-04-03 16:50; UTC

Svarbiausios naujienos

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

2026-04-03 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-04-03 16:12; UTC

Uždarbis

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

2026-04-03 15:56; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

2026-04-03 15:56; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Global Equities Roundup: Market Talk

2026-04-03 15:56; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Global Forex and Fixed Income Roundup: Market Talk

2026-04-03 15:20; UTC

Svarbiausios naujienos

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

2026-04-03 15:08; UTC

Įsigijimai, susijungimai, perėmimai

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

2026-04-03 14:11; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

2026-04-03 12:56; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

2026-04-03 08:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-04-03 08:01; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-03 08:01; UTC

Rinkos pokalbiai

Meituan's Profitability Likely to Improve This Year -- Market Talk

2026-04-03 07:45; UTC

Rinkos pokalbiai

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

2026-04-03 06:17; UTC

Rinkos pokalbiai

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

2026-04-03 06:17; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-03 04:33; UTC

Rinkos pokalbiai

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

2026-04-03 04:33; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-03 04:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-04-03 04:01; UTC

Rinkos pokalbiai

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

2026-04-03 02:01; UTC

Rinkos pokalbiai

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

2026-04-03 01:59; UTC

Rinkos pokalbiai

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

2026-04-03 01:44; UTC

Rinkos pokalbiai

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

2026-04-03 01:22; UTC

Rinkos pokalbiai

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

29.95% į viršų

12 mėnesių prognozė

Vidutinis 97.19 USD  29.95%

Aukščiausias 120 USD

Žemiausias 72 USD

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

14 ratings

11

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

154 / 349 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat